Moderna

Moderna, Inc. is an American biotechnology company that focuses on messenger RNA (mRNA) therapeutics and vaccines. Headquartered in Cambridge, Massachusetts, the company was founded in 2010 by Derrick Rossi with strategic support from Flagship Pioneering; Stéphane Bancel became chief executive officer in 2011. Moderna went public in December 2018 and trades on the Nasdaq under the ticker MRNA.

Moderna develops medicines by designing mRNA sequences that code for specific proteins, which are delivered into cells using lipid nanoparticles. This approach aims to prompt the body's own cells to produce therapeutic proteins. The company’s platform is applied to vaccines as well as therapeutics for infectious diseases, cancer immunotherapies, and rare genetic conditions, with an emphasis on rapid design and scalable manufacturing.

A key program during the COVID-19 pandemic was mRNA-1273, marketed as Spikevax, developed with the National Institute of Allergy and Infectious Diseases (NIAID). The vaccine received emergency use authorization from the U.S. Food and Drug Administration in late 2020 and later achieved full FDA approval for adults in 2022. Moderna expanded its manufacturing capacity for Spikevax and engaged in international supply and collaboration agreements to meet demand.

Beyond COVID-19, Moderna pursues vaccines and therapeutics across other infectious diseases, as well as oncology vaccines and therapies, leveraging its mRNA platform. The company maintains collaborations with government agencies, academic researchers, and industry partners to advance its pipeline and address unmet medical needs.

---